SUTOL BIO, Inc.
StreetZero Signal 69
About SUTOL BIO, Inc.
SUTOL Bio develops a first-in-class gastric-resident Monthly Oral Capsule Platform that delivers continuous drug release for more than 30 days from a single dose. The technology originated from six years of translational research in the Langer and Traverso labs at MIT. It aims to eliminate the need for daily pills or painful injections. The company is headquartered in Cambridge, MA, with founders Seungho Lee and Matt Murphy.
LATEST FUNDINGPrivate Placement
$474K
Announced 2026-11-10
TOTAL RAISED$474,000
IN THE NEWS
EMPLOYEES—
FOUNDED—
HQCambridge, MA, United States
Industry
Biotechnology
Tags
BiotechnologyDrug DeliveryOral TherapeuticsMIT Spinout
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Developing monthly oral capsule for 30+ days continuous therapy.
- Spin-out from Langer and Traverso labs at MIT.
- Resident company at The Engine accelerator.
- Targeting elimination of daily pills and injections.
- Raised $474k via private placement in Cambridge, MA.
Ask StreetZero about SUTOL BIO, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account